PMC:7565665 / 60292-60606
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T406 | 177-179 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T722 | 135-139 | http://purl.obolibrary.org/obo/PR_000001044 | denotes | CFTR |
| T723 | 197-201 | http://purl.obolibrary.org/obo/PR_000001044 | denotes | CFTR |
| T724 | 290-296 | http://purl.obolibrary.org/obo/UBERON_0001005 | denotes | airway |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T56457 | 12-22 | Chemical | denotes | cysteamine | http://purl.obolibrary.org/obo/CHEBI_17141|http://purl.obolibrary.org/obo/CHEBI_58029 |
| T80 | 72-83 | Chemical | denotes | antioxidant | http://purl.obolibrary.org/obo/CHEBI_22586 |
| T73677 | 99-108 | Chemical | denotes | mucolytic | http://purl.obolibrary.org/obo/CHEBI_77034 |
| T72726 | 177-179 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1500 | 135-139 | Gene | denotes | CFTR | Gene:1080 |
| 1505 | 12-22 | Chemical | denotes | cysteamine | MESH:D003543 |
| 1519 | 197-213 | Disease | denotes | CFTR dysfunction | MESH:D009461 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T819 | 135-139 | http://purl.obolibrary.org/obo/GO_0005260 | denotes | CFTR |
| T820 | 197-201 | http://purl.obolibrary.org/obo/GO_0005260 | denotes | CFTR |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T315 | 0-314 | Sentence | denotes | Even though cysteamine offers several beneficial attributes such as its antioxidant, bactericidal, mucolytic, and, the most promising, CFTR-rescuing potential that corrects the CS-induced acquired CFTR dysfunction, there are some limitations such as the optimization of beneficial dose and airway delivery methods. |